



43rd Annual NCDEU Meeting PROGRAM

May 27-30, 2003 Boca Raton, Florida

Monday, May 26, 2003

New Investigator's Workshop (Closed)

8:30 am- 5:30 pm

Tuesday, May 27, 2003

WORKSHOP 1

9:00 AM - 12:00 Noon

Complementary and Alternative Treatments: Research Challenges

Chairs:

Andrew A. Nierenberg, M.D., (Harvard Medical School)
Nancy J. Pearson, Ph.D., (National Center for Complementary and
Alternative Medicine)

Introduction

NCCAM: Overcoming Challenges to Clinical Trials with Natural Products,
Margaret A. Chesney, Ph.D., (National Center for Complementary and Alternative Medicine)

***Basic Mechanisms: Nuclear Xenobiotic Receptor PXR: A Molecular Target for
St. John's Wort***

Steven A. Kliewer, Ph.D., (University of Texas - Southwestern Medical Center)

Break

Adventures with the Herbal Industry: Vetting the Source for St. John's Wort
Andrew A. Nierenberg, M.D., (Harvard Medical School)

Fishing for Efficacy: the Omega-3 Story
David Mischoulon, M.D., Ph.D., (Harvard Medical School)

***The Ginkgo in Evaluation of Memory (GEM) Dementia Prevention Trial: Challenges and
Opportunities***

Steven T. DeKosky, M.D., University of Pittsburgh

General discussion and conclusions

Tuesday, May 27, 2003

WORKSHOP 2

Enhancing Precision in Clinical Trials VI

Part 1: 9:00 AM - 12:00 Noon

Part 2: 1:00 PM - 5:00 PM

Chair: Mark Rapaport, M.D., Cedars-Sinai Hospital

Morning Session (9 a.m. – 12 p.m.) Applications

- | | |
|--------------------|--|
| 9:00 – 9:05 a.m. | <i>Introduction and Opening Remarks on Applications</i>
Mark Rapaport (Cedars-Sinai Hospital) |
| 9:05 – 9:40 a.m. | <i>Patient-based quality of life and health outcomes assessment</i>
John Ware (QualityMetric) |
| 9:40 – 10:15 a.m. | <i>IVR diary methods to reduce retrospective recall bias in sleep studies</i> Bernice Kuca (Sepracor) |
| 10:15 – 10:30 a.m. | Break |
| 10:30 – 11:05 a.m. | <i>Traditional vs. Enriched Rater Training for a Multi-Site Depression Trial: A pilot study of effectiveness and feasibility</i>
Nina Engelhardt (Eli Lilly) |
| 11:05 – 11:40 a.m. | <i>Assessing Patients in Psychiatric Drug Trials: A Regulatory Perspective:</i> Tom Laughren (FDA) |
| 11:40 – Noon | <i>Wrap-up and Concluding Comments on Application</i>
Mark Rapaport (Cedars-Sinai Hospital) |

Afternoon Session (2 p.m. – 5 p.m.): Theory

- | | |
|------------------|---|
| 2:00 – 2:05 p.m. | <i>Introduction and Opening Remarks on Theory</i>
Mark Rapaport (Cedars-Sinai Hospital) |
| 2:05 – 2:40 p.m. | <i>An activity update for the NIMH Conference, Assessment of Depression and Anxiety in Depression Treatment Trials</i>
David Kupfer (Western Psychiatric) |
| 2:40 – 3:15 p.m. | <i>Methodological Issues arising from the Pregabalin and Sertraline Trials in Generalized Anxiety Disorder</i> Catherine Clary (Pfizer) |
| 3:15 – 3:30 p.m. | Break |
| 3:30 – 4:05 p.m. | <i>New self-report assessments and methodological issues in clinical trials</i> David DeBrotta (Eli Lilly) |
| 4:05 – 4:40 p.m. | <i>Update on study methodology and self-report in a very large NIMH trial:</i> A. John Rush (University of Texas Southwestern) |
| 4:40 – 5:00 p.m. | <i>Wrap-up and Concluding Comments on Theory,</i> Mark Rapaport (Cedars-Sinai Hospital) |

Tuesday, May 27, 2003

WORKSHOP 3

Beyond Short-Term Treatment Effects: Can We Change the Course of Illness Through Treatment?

Part 1: 9:00 AM - 12:00 Noon

Part 2: 1:00 PM - 5:00 PM

Morning Session (9 a.m. – 12 p.m.) **Studying Possible Long-Term Effects of Interventions**

Chair: Benedetto Vitiello, M.D., NIMH

- | | |
|-----------------------|--|
| 9:00 am – 9:10 am | Introduction |
| 9:10 am – 9:50 am | <i>Extended follow-up in the multimodal treatment study of children with ADHD (MTA)</i>
L. Eugene Arnold, M.D. (Ohio State University) |
| 9:50 am – 10:30 am | <i>The effect of stimulant medication on outcomes of adolescents and young adults with ADHD</i>
William Pelham, (State University of New York at Buffalo) |
| 10:30 am – 10:40 am | Break |
| 10:40 am – 11:20 am | <i>Are there persistent effects of cognitive-behavioral therapy in depressed adolescents?</i>
Gregory Clark, Ph.D., (Kaiser Research Foundation) |
| 11:20 am – 12:00 noon | <i>Detecting distal effects on low base-rate disorders: what can we learn from prevention research?</i>
Hendricks Brown, Ph.D., (University of South Florida) |
| 12:00 noon | Lunch break |

Afternoon Session (1:00 p.m. – 5:00 p.m.): **Studying the Long-Term Safety of Pharmacological Treatment in Children**

Chair: Laurence L. Greenhill, M.D., (Columbia University)

- | | |
|-------------------|--|
| 1:30 pm – 2:10 pm | <i>Is there a European regulatory perspective to studying long-term pharmacological effects in naturalistic settings?</i>
Joerg Fegert, M.D., (University of Ulm) |
| 2:10 pm – 2:50 pm | <i>Stimulant medications and growth in children with ADHD</i>
James Swanson, Ph.D., (University of California at Irvine) |
| 2:50 pm – 3:20 pm | <i>Stimulant medications and risk of substance abuse</i>
Lily Hechtman, M.D., (McGill University) |
| 3:20 pm – 3:30 pm | Break |

- 3:30 pm – 4:10 pm ***Childhood methylphenidate and substance involvement 30 years later: methodological considerations***
Jan Loney, Ph.D., (University of Iowa)
- 4:10 pm – 4:50 pm ***Long-term treatment of children with autism with risperidone.***
Michael Aman, Ph.D., (Ohio State University)
- 4:50 pm – 5:00 pm **General discussion and conclusions**

Tuesday, May 27, 2003

WORKSHOP 4

Subject Diversity in Clinical Trials: Is Recruitment Enough?

2:00 PM – 5:00 PM

Chairs: William B. Lawson MD, PhD, (Howard University)
Sherman L. Ragland, M.S.W., (National Institute of Mental Health)

Dorothy on the Yellow Brick Road: Innovation, Infrastructure and Diversity in Clinical Trials

Keh Min Lin, M.D., MPH, (Harbor-UCLA Research and Education Institute)

Tanya N. Alim, M.D., (Howard University)

Special Issues for the Recruitment, Retention, and Assessment of Older People with Psychotic Disorders in Clinical Trials

Jonathan P. Lacro, Pharm.D., (VA San Diego Healthcare System and University of California, San Diego)

Subject Diversity in Clinical Trials: From schizophrenia to Refugee Populations

David C. Henderson, M.D., (Massachusetts General Hospital)

TREATMENT DEVELOPMENT SESSION 1

Pharmacogenetics of Mood and Anxiety Disorders

9:00 AM - 11:00 AM

Chair: Francis McMahon, M.D., (National Institute of Mental Health)

- 9:00 am-9:30 am ***Tackling the genetics of pharmacogenomics***
Francis J McMahon, MD, (National Institute of Mental Health)
- 9:30 am-10:00 am ***Recent Advances and Clinical Applications of Pharmacogenetics in Psychiatry***
TBA
- 10:00 am-10:30 am ***Pharmacogenetics of mood stabilization in bipolar disorder***
Martin Alda, MD, FCRPC. (Dalhousie University, Halifax, Canada)

10:30 am-11:00 am **Panel Discussion**

Tuesday, May 27, 2003

TREATMENT DEVELOPMENT SESSION 2

New Approaches in Drug Discovery

1:00 PM - 3:00 PM

Chair: Linda S. Brady, Ph.D., (National Institute of Mental Health)

- | | |
|------------------|---|
| 1:00 pm – 1:30pm | <i>Screening the Receptorome Reveals Unexpected Targets for Drug Discovery</i>
Bryan Roth, Ph.D., (Case Western Reserve University) |
| 1:30 pm – 2:00pm | <i>PET Studies of CNS NK1 Receptors with [18F]SPA-RQ in the Clinical Development of Substance P Antagonists</i>
Richard Hargreaves, Ph.D. (Merck) |
| 2:00 pm – 2:30pm | <i>Psychiatric Genomics: Gene-Based Target Identification for Schizophrenia, Depression, and Bipolar Disease</i>
C Anthony Altar, Ph.D., (Psychiatric Genomics, Inc.) |
| 2:30 pm – 3:00pm | <i>A Novel Class of Nucleic Acid Drugs</i>
Errol DeSouza, Ph.D., (Archemex Corp.) |

TREATMENT DEVELOPMENT SESSION 3

MATRICES: Treatment Development for Cognition in Schizophrenia

3:30 PM - 5:00 PM

Chair: Stephen R. Marder, M.D., (UCLA and VA Greater Los Angeles)

- | | |
|-------------------|---|
| 3:30 pm – 3:45pm | Treatment Development for Neurocognition in Schizophrenia
Wayne S. Fenton, M.D., (National Institute of Mental Health) |
| 3:45 pm – 4:00pm | Separable Cognitive Factors in Schizophrenia
Keith Nuechterlein, Ph.D., (UCLA) |
| 4:15pm – 4:30pm | Cognition and Functional Outcome in Schizophrenia
Michael Green, Ph.D., (UCLA) |
| 4:30 pm – 4:45pm | Pharmacological Interventions for Cognition in Schizophrenia
Robert W. Buchanan, M.D., (Maryland Psychiatric Research Center) |
| 4:45 pm – 5:00pm | NIMH/UCLA MATRICES Overview and Timeline
Stephen R. Marder, M.D., (UCLA and VA Greater Los Angeles) |
| 7:00 pm – 7:30pm | <i>New Investigators' Awards Presentation</i> (Open) |
| 7:30 pm – 9:30 pm | <i>Reception</i> (Open) |

Wednesday, May 28, 2003

Welcome and News from NIMH

8:30 AM – 9:30 AM

Welcome to NCDEU

Matthew V. Rudorfer, M.D.

NCDEU Program Chair

National Institute of Mental Health

Grayson S. Norquist, M.D., M.S.P.H.

Director, Division of Services and Intervention Research

National Institute of Mental Health

NIMH News and Updates

Thomas R. Insel, M.D.

Director, National Institute of Mental Health

Richard K. Nakamura, Ph.D.

Deputy Director

National Institute of Mental Health

Dennis S. Charney, M.D.

Director, Mood and Anxiety Disorders Program

National Institute of Mental Health

9:30 am – 9:55 am

Break

PLENARY SESSION: *Treatment and Preventive Interventions Research: From Laboratory through Clinical Trial to Practice*

10:05 AM - 12:15 PM

Chair: Wayne S. Fenton, M.D., (National Institute of Mental Health)

CNS Drug Development in the 21st Century

Edward M. Scolnick, M.D., (Merck)

Novel Targets and Approaches to Affective and Anxiety Disorders

Dennis S. Charney, M.D., (National Institute of Mental Health)

Novel Targets and Approaches to Schizophrenia

Carol A. Tamminga, M.D., (University of Maryland School of Medicine)

Science to Service

Discussant: A. John Rush, M.D., (University of Texas Southwestern Medical Center)

PANEL 1

2:15 PM - 4:15 PM

Improving the Clinical Relevance of Maintenance Designs in Bipolar Disorder

Chair: Charles L. Bowden, M.D., (University of Texas Health Science Center, San Antonio)

- 2:15 pm – 2:45 pm ***Choosing the Right Patient Population***
Terrence Ketter, M.D., (Stanford University)
- 2:40 pm – 3:10pm ***Choosing the Right Outcomes***
Charles L. Bowden, M.D., (University of Texas Health Science Center, San Antonio)
- 3:10 pm – 3:40pm ***Systematic Open Studies and Randomized, Placebo Controlled Studies***
William H. Coryell, M.D., (University of Iowa)
- 3:40 pm – 4:10pm ***Working in a Complex Environment: The Multiple Challenges in Studying Psychosocial Treatments for Bipolar Disorder***
Ellen Frank, Ph.D., (University of Pittsburgh)
- 4:10 pm ***Bridging the Efficacy vs Effectiveness Gap***
Discussant: Matthew V. Rudorfer, M.D., (National Institute of Mental Health)

Wednesday, May 28, 2003

PANEL 2

2:15 PM - 3:45 PM

Integration of Neurobiologic Methods into Late-Life Clinical Trials

Chairs: Gwenn Smith, Ph.D., (Zucker Hillside Hospital, North Shore - Long Island Jewish Health System)
William Z. Potter, M.D., Ph.D., (Eli Lilly and Company)

- 2:15 pm – 2:35 pm ***Role of Structural neuroimaging***
David C. Steffens, M.D., M.H.S., (Duke University Medical Center)
- 2:35 pm – 2:55 pm ***Integration of neurochemical brain imaging with clinical trials-neurochemical substrates of treatment response variability***
Gwenn Smith, Ph.D., (Zucker Hillside Hospital, North Shore - Long Island Jewish Health System)
- 2:55 pm – 3:15 pm ***Integration of biological measures into clinical trials in psychotic depression***
Barnett S. Meyers, M.D., (Weill Medical College of Cornell University)
- 3:15 pm – 3:45 pm ***Future Directions in treatment development and biological markers***
William Z. Potter, M.D., Ph.D., (Eli Lilly and Company)

Wednesday, May 28, 2003

PANEL 3

4:30 PM - 6:00 PM

Proof of Concept Trials in Neuropsychiatric Disorders

Chairs: Herbert Harris, (Vela Pharmaceuticals)
Remy Luthringer, (Forenap Institute)

4:30pm – 4:35pm	General Introduction Herbert Harris, M.D., Ph.D., (Vela Pharmaceuticals)
4:35pm – 4:55pm	<i>The Emerging Scope of Proof of Concept</i> William Z. Potter, M.D., Ph.D. (Eli Lilly)
4:55pm – 5:15pm	<i>Genomics in Proof of Concept Trials</i> Maria Athanasiou, Ph.D., (Genaissance Pharmaceuticals)
5:15pm – 5:35pm	<i>CNS Disease Modeling in Human Subjects</i> Remy Luthringer, Ph.D, (Forenap Institute)
5:35pm – 6:00pm	Discussion: <i>The Proof of Proof of Concept</i> Paul Andreason, M.D. , (Food and Drug Administration) Barry Lebowitz, Ph.D. (National Institute of Mental Health) Fouzia Laghrissi-Tode, M.D., (Roche)

Wednesday, May 28, 2003

UPDATES -I

4:00 PM - 6:00 PM

Chair: Susan M. Essock, Ph.D., (Mount Sinai School of Medicine)

UPDATE 1

Medical Monitoring for Individuals with Schizophrenia: Results from a Consensus Conference

Stephen R. Marder, M.D., (UCLA and VA Greater Los Angeles)

UPDATE 2

Risk Management in Clinical Trials

Madhukar Trivedi, M.D., (University of Texas – Southwestern Medical School)

UPDATE 3

Research Design Features Determining Antidepressant Clinical Trial Outcome

Arif Khan, M.D., (Northwest Clinical Research Center)

UPDATE 4

Impulse Control Disorders: Neurobiology and Treatment

Larry J. Siever, M.D., (Mount Sinai School of Medicine)

Wednesday, May 28, 2003

TREATMENT DEVELOPMENT SESSION 4

2:15 PM - 3:45 PM

Case Studies: Drug Registration for Non-DSM Indications

Chair: Roger E. Meyer, M.D. Best Practices, LTD

2:15 pm – 2:40 pm ***Clozapine as a Treatment for Suicidality in Schizophrenia: Background, Design, and Results of INTERSEPT Study***
Larry Alphs, M.D., (Novartis)

2:40 pm – 3:15 pm ***Can Clinical, Commercial and Regulatory Reality Converge? A Case Study: Psychosis of Dementia***
George Gharabawi, M.D., (Janssen Pharmaceutica)

3:15 pm – 3:40 pm ***Challenges to Evaluating Agitation in Acute Psychosis: Establishing Parameters for a New Indication***
Steven J. Romano, M.D., Pfizer, Inc.

3:40 pm – 3:45 pm **Discussant:** Thomas A. Laughren, M.D., (Food and Drug Administration)

Wednesday, May 28, 2003

TREATMENT DEVELOPMENT SESSION 5

4:00 PM - 6:00 PM

Innovative, Mechanism-Based Treatment Strategies in Anxiety and Depression

Chairs: Alan F. Schatzberg, M.D., (Stanford University)
K. Ranga R. Krishnan, M.D., (Duke University)

4:00 pm – 4:30 pm ***Replication of the Efficacy and Tolerability of Substance P Antagonists in Patients with Major Depression***
William A. Ball, M.D., Ph.D., (Merck)

4:30 pm – 5:00 pm ***Acute Treatment of Bipolar Depression with an Olanzapine-Fluoxetine Combination***
Gary C. Tollefson, M.D., Ph.D., (Eli Lilly and Company)

5:00 pm – 5:30 pm ***Clinical Trials of Mifepristone for Psychotic Major Depression (PMD)***
Joseph Belanoff, M.D., (Corcept Therapeutics, Inc.)

5:30 pm – 6:00 pm ***The Role of Glutamate Antagonists in the Treatment of Anxiety***
K. Ranga R. Krishnan, M.D., (Duke University)

12:15 pm – 2:15 pm **Poster Session I**

7:00 pm – 9:00 pm **NIMH Reception (Open)**

Thursday, May 29, 2003

6:30 am – 7:30 am **5th Annual Fun Run/Walk (Open)**

PANEL 4

Psychopharmacology and Reproductive Transitions

9:00 AM - 12:00 Noon

Chair: Mary C. Blehar, Ph.D., National Institute of Mental Health

9:00 am – 9:30 am Sandra L. Kweder, M.D., (Food and Drug Administration)

9:30 am – 10:00 am ***Weight-Gain Inducing Psychotropic Medications, Gender, and Potential Pharmacologic Strategies***
Barbara L. Gracious, M.D., (University of Rochester)

- 10:00 am – 10:30 am ***Testosterone Decline in Aging Men: Does “Andropause” Exist?***
Stuart N. Seidman, M.D., (Columbia University)
- 10:30 am – 11:00 am ***Perimenopause, Mood, and Estrogens***
Claudio N. Soares, M.D., Ph.D., (Massachusetts General Hospital)
- 11:00 am – 11:30 am ***Women’s Health Initiative***
Sally Shumaker, Ph.D.
- 11:30 am – 12:00 pm **General Discussion**

Thursday, May 29, 2003

PANEL 5

9:00 AM - 10:30 AM

Cocaine Dependence Treatment: Advances in Agonist Strategies and Behavior Therapy – Pharmacotherapy Combinations

Chairs: Jack D. Blaine, M.D., (National Institute on Drug Abuse)
John Grabowski, Ph.D., (University of Texas Health Science Center, Houston)

- 9:00 am – 9:15 am ***NIDA Medication Development Program***
Ahmed Elkashef, M.D., National Institute on Drug Abuse
- 9:15 am – 9:30 am ***Effects of Continuous Infusion with Amphetamine on Cocaine Self-Administration and Food-Maintained Responding in Rhesus Monkeys***
S. Steven Negus, Ph.D., (McLean Hospital and Harvard Medical School)
- 9:30 am – 9:45 am ***Biogenic Amine Releasing Agents as Agonist Substitution Therapies for Stimulant Dependence***
Michael H. Baumann Ph.D., (National Institute on Drug Abuse)
- 9:45 am – 10:00 am ***Clinical Trials Large and Small of Agonists for Cocaine Dependence: Support for a Conceptual Model and Medication Development***
John Grabowski, Ph.D., (University of Texas Health Science Center, Houston)
- 10:00 am – 10:15 am ***Combining Medication and Behavior Therapy for Cocaine Dependence***
Joy Schmitz, Ph.D., (University of Texas Health Science Center, Houston)
- 10:15 am – 10:30 am **General Discussion**

Thursday, May 29, 2003**PANEL 6**

2:30 PM - 4:00 PM

Advances in Medication Adherence in Psychotic Disorders

Chairs: Dawn I. Velligan, Ph.D., (University of Texas Health Science Center, San Antonio)
 Nina R. Schooler, Ph.D., (Zucker Hillside Hospital, North Shore - Long Island Jewish Health System)

- 2:30 pm – 2:45 pm ***Medication Adherence and Bipolar Disorder***
 Gary Sachs, M.D., (Massachusetts General Hospital)
- 2:45 pm – 3:00 pm ***Medication Adherence and Schizophrenia***
 Peter Weiden, M.D., (SUNY Health Science Center at Brooklyn)
- 3:00 pm – 3:15 pm ***How to Assess Medication Adherence in Psychotic Disorders***
 Francis Lam, Pharm.D., (University of Texas Health Science Center, San Antonio)
- 3:15 pm – 3:30 pm ***Improving Adherence to Medications***
 Dawn I. Velligan, Ph.D., (University of Texas Health Science Center, San Antonio)
- 3:30 pm – 3:45 pm **Discussant:** Nina R. Schooler, Ph.D., (Zucker Hillside Hospital, North Shore - Long Island Jewish Health System)
- 3:45 pm – 4:00 pm **General Discussion**

Thursday, May 29, 2003**PANEL 7**

2:30 PM - 5:30 PM

Brain Imaging Markers of Pharmacological Treatment in Children, Adolescents, and Adults

Chairs: Judith M. Rumsey, Ph.D., (National Institute of Mental Health)
 Michael E. Henry, M.D., (McLean Hospital)

Clinical Studies – Chair: Judith M. Rumsey, Ph.D.

- 2:30 pm – 2:55 pm ***Using Neuroimaging to Assess the Effects of Antipsychotic Treatment in Youth with Schizophrenia***
 Linmarie Sikich, M.D., (University of North Carolina, Chapel Hill)
- 2:55 pm – 3:20 pm ***fMRI of Inhibition and Stimulant Response in ADHD***

Steven R. Pliszka M.D., (University of Texas Health Science Center at San Antonio)

3:20 pm – 3:45 pm ***MRS-Detected Brain Chemistry and Treatment Response in Pediatric OCD and Major Depressive Disorder***
David R. Rosenberg, M.D., (Wayne State University School of Medicine)

3:45 pm – 3:55 pm **Break**

Drug Development – Chair: Michael E. Henry, M.D.

3:55 pm – 4:20 pm ***Imaging With the Drug Companies, What Can We Expect?***
Mark E. Schmidt, M.D. and Patricia Cole, Ph.D., M.D., (Novartis Neuroscience and Pharmaceuticals)

4:20 pm – 4:45 pm ***Development and Application of Amyloid Imaging Agents for PET***
C.A. Mathis, Ph.D., (University of Pittsburgh)

4:45 pm – 5:10 pm ***The Use of ¹⁹-F MRS to Assess Pharmacokinetics in the CNS***
Michael E. Henry, M.D.

5:10 pm – 5:30 pm **General Discussion**

Thursday, May 29, 2003

PANEL 8

4:15 PM - 5:45 PM

New Treatment Developments for Somatoform Disorders

Chair: Javier I. Escobar, M.D., (Robert Wood Johnson Medical School)

4:15 pm – 4:30 pm ***Cognitive-Behavioral Therapy in the Treatment of Full Somatization Disorders***
Lesley Allen, Ph.D., (Robert Wood Johnson Medical School)

4:30 pm – 4:45 pm ***A Randomized, Controlled Intervention Trial of Cognitive-Behavior Therapy for Hypochondriasis***
Arthur J. Barsky, M.D., (Harvard University)

5:00 pm – 5:15 pm ***CBT in the Treatment of Gulf War and Other "Functional" Syndromes***
Charles Engel, M.D., MPH, Uniformed Services University of the Health Sciences

5:15 pm – 5:30 pm ***CBT in the Treatment of Somatization in Primary Care***
Javier I. Escobar, M.D.

5:30 pm – 5:45 pm **General Discussion**

Thursday, May 29, 2003

UPDATES-II

10:45 AM - 12:15 PM

UPDATE 5

Novel Medication Delivery Systems

Herbert W. Harris, M.D., Ph.D., (Vela Pharmaceuticals)

UPDATE 6

Relapse Detection and Prevention in Anxiety Disorders

Matig Mavissakalian, M.D., (Case Western Reserve University)

UPDATE 7

Increasing Psychotropic Drug Response Predictability in African Americans and other Minorities

DiAnne Bradford, Ph.D., (Morehouse School of Medicine)

Thursday, May 29, 2003

TREATMENT DEVELOPMENT SESSION 6

9:00 AM - 11:00 AM

Cognition Across Diagnostic Entities: Shared and Unique Aspects of Cognitive Impairment Across Depression, Bipolar Disorder, Alzheimer's Disease, Schizophrenia, and NeuroAIDS

Chair: Michael Green, Ph.D., UCLA

- | | |
|---------------------|--|
| 9:00 am – 9:25 am | <i>Cognitive Impairment in Affective Disorders</i>
Wilfred G. van Gorp, Ph.D., (Columbia University) |
| 9:25 am – 9:50 am | <i>Cognition and NeuroAIDS</i>
Robert K. Heaton, Ph.D., (University of California, San Diego) |
| 9:50 am – 10:15 am | <i>Cognitive Deficits of Alzheimer's Disease</i>
Alfred W. Kaszniak, Ph.D., University of Arizona |
| 10:15 am – 10:35 am | <i>Cognitive Impairments in Schizophrenia</i>
Ruben C. Gur, Ph.D., University of Pennsylvania |
| 10:35 am – 11:00 am | Discussant: Keith Nuechterlein, Ph.D., UCLA |

Thursday, May 29, 2003

TREATMENT DEVELOPMENT SESSION 7

11:00 AM - 12:30 PM

Novel Target-Driven Strategies for the Treatment of Mood and Anxiety Disorders

Chair: Husseini K. Manji, M.D., (National Institute of Mental Health)

11:00 am – 11:15 am	<i>MGluR2/3 Receptors: A Neuroanatomically Selective Target with Relevance for Pathological Stress and Anxiety</i> Gary D. Tollefson, M.D., Ph.D., (Eli Lilly and Company)
11:15 am – 11:30 am	<i>Ampakines</i> Mo Shahid, M.D., (Organon)
11:30 am – 11:45 am	<i>NPY Signaling</i> Markus Helig, M.D., (Karolinska Institute)
11:45 am – 12:00 am	<i>The Role of Extracellular Signal-Regulated Kinase (ERK) Pathway in Mood-Modulation</i> Guang Chen, M.D., Ph.D., (National Institute of Mental Health)
12:00 am – 12:30 pm	General Discussion

Thursday, May 29, 2003

TREATMENT DEVELOPMENT SESSION 8

2:30 PM - 4:30 PM

Thinking Outside the Box: Future Directions in the Treatment of ADHD, Mood, and Anxiety Disorders in Children

Chair: Ellen Leibenluft, M.D., National Institute of Mental Health Intramural Research Program

2:30 pm – 2:55 pm	<i>Use of Psychotropic Drugs in Children: A Pre-Clinical Perspective</i> Susan L. Andersen, Ph.D., (McLean Hospital)
2:55 pm – 3:20 pm	<i>Breakthroughs in Pharmacological and Psychological Treatments for ADHD</i> James Swanson, Ph.D., (University of California, Irvine)
3:20 pm – 3:45pm	<i>New Directions in the Psychopharmacology of Pediatric Anxiety</i> Daniel S. Pine, M.D., (National Institute of Mental Health)
3:45 pm – 4:10 pm	<i>Future Directions in the Treatment of Pediatric Bipolar Disorder</i> Ellen Leibenluft, M.D., (National Institute of Mental Health)
4:10 pm – 4:30 pm	General Discussion

Thursday, May 29, 200312:30 pm – 2:30 pm **Poster Session II****Friday, May 30, 2003****FDA Symposium**

9:00 AM - 12:00 Noon

Chairs: Russell Katz, M.D. and Thomas Laughren, M.D.
Food and Drug Administration

- | | |
|-------------------------|--|
| 9:00 a.m. – 9:30 a.m. | <i>Surrogate Markers: Regulatory and Scientific Issues</i>
Russell Katz, M.D. |
| 9:30 a.m. – 10:00 a.m. | <i>Regulatory View of Cognitive Deficits in Schizophrenia as a Target for Drug Development</i>
Thomas Laughren, M.D. |
| 10:00 a.m. – 10:30 a.m. | <i>An Association Between Atypical Antipsychotic Drug Use and Cerebrovascular Adverse Events in Patients with Dementia</i>
Tarek Hammad, M.D., Ph.D. |
| 10:30 a.m. – 11:00 a.m. | <i>Lumping or Splitting in Drug Claims: Mood and Physical Symptoms of Premenstrual Dysphoric Disorder (Case in Point)</i>
Karen Brugge, M.D. |
| 11:00 a.m. – 11:30 a.m. | <i>Blood (Sweat and Tears): The Role of Concentration Data in Regulatory Review</i>
Cara Alfaro, Pharm.D. |
| 11:30 a.m. – 12:00 p.m. | General Discussion |

Adjourn at noon

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
NATIONAL INSTITUTES OF HEALTH • NATIONAL INSTITUTE OF MENTAL HEALTH

